Lymphomas: Our Clinical Trials

In addition to providing excellent care, Memorial Sloan Kettering Cancer Center is constantly working to develop new and improved treatments for people with lymphoma who are not helped by standard treatments. This research is conducted through our clinical trials program.

Our physicians lead a large number of clinical trials that test new drugs and drug combinations, look for genetic factors that are linked to lymphoma, and explore other strategies for improving treatment for both Hodgkin and non-Hodgkin lymphoma. Our clinical trials are based on our growing understanding of how lymphoma is distinctive from other cancers. This research is increasingly “translational,” bringing discoveries made in the research lab directly to the patient.

This activity means that choosing Memorial Sloan Kettering for your care may give you access to new treatment options before they are widely available elsewhere. Our clinical research team is highly experienced in selecting patients who are mostly likely to benefit from a particular investigational therapy and can guide you through the process of selecting the most appropriate clinical trial.

Our research efforts fall into the following general categories:

New chemotherapy approaches

Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphoma.

Pathway-directed (biologic) therapies

Our investigators are testing drugs designed to interrupt or inhibit the molecular processes tumor cells require to grow and spread.

Immune strategies

Memorial Sloan Kettering has an active immunotherapy program testing investigational drugs that encourage the body's immune system to identify and react against cancer cells.

Tumor-directed therapies (radiolabeled antibodies)

Memorial Sloan Kettering researchers are investigating the effectiveness of antibodies — proteins that specifically target cancer cells and carry radioactive molecules. These drugs can potentially kill cancer cells with radiation while minimizing exposure to the rest of the body.

Here you can find a continually updated listing of Memorial Sloan Kettering's current clinical trials for patients with lymphomas. To learn more about a study, choose from the list below.

Marginal Zone Lymphoma

Follicular Lymphoma

Untreated (Newly Diagnosed)

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]

Prior Treatment (Relapsed/Refractory)

A Phase IB/IIA Study of Carfilzomib, Romidepsin, and Lenalidomide in Patients with Recurrent or Persistent Lymphoma
Horwitz, Steven, MD
[Protocol 14-179]

A Phase IB Study of MPDL3280A plus Obinutuzumab in Patients with Recurrent or Persistent Lymphoma
Palomba, M. Lia, MD
[Protocol 14-220]

A Phase II Study of Mocetinostat in Patients with Diffuse Large B-cell Lymphoma or Follicular Lymphoma with Certain Mutations
Younes, Anas, MD
[Protocol 14-106]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]

A Phase I Study of PU-H71 in Patients with Advanced Cancer
Gerecitano, John, MD, PhD
[Protocol 11-041]

Small Lymphocytic Lymphoma (SLL)

Diffuse Large B-Cell Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Ibrutinib (PCI-32765) plus R-CHOP Chemotherapy in Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
Younes, Anas, MD
[Protocol 13-146]

A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
Noy, Ariela, MD
[Protocol 13-022]

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]

Prior Treatment (Relapsed/Refractory)

A Phase IB/IIA Study of Carfilzomib, Romidepsin, and Lenalidomide in Patients with Recurrent or Persistent Lymphoma
Horwitz, Steven, MD
[Protocol 14-179]

A Phase IB Study of MPDL3280A plus Obinutuzumab in Patients with Recurrent or Persistent Lymphoma
Palomba, M. Lia, MD
[Protocol 14-220]

A Phase II Study of Mocetinostat in Patients with Diffuse Large B-cell Lymphoma or Follicular Lymphoma with Certain Mutations
Younes, Anas, MD
[Protocol 14-106]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]

A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Sauter, Craig, MD
[Protocol 14-145]

A Phase I Study of PU-H71 in Patients with Advanced Cancer
Gerecitano, John, MD, PhD
[Protocol 11-041]

Hodgkin Lymphoma

Mantle Cell Lymphoma

Burkitt's Lymphoma

Untreated (Newly Diagnosed)

A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
Noy, Ariela, MD
[Protocol 13-022]

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]

Prior Treatment (Relapsed/Refractory)

A Phase IB/IIA Study of Carfilzomib, Romidepsin, and Lenalidomide in Patients with Recurrent or Persistent Lymphoma
Horwitz, Steven, MD
[Protocol 14-179]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]

A Phase I Study of PU-H71 in Patients with Advanced Cancer
Gerecitano, John, MD, PhD
[Protocol 11-041]

T Cell Lymphoma

HIV+ Lymphoma

Waldenstrom's Macroglobulinemia

Adult T Cell Leukemia Lymphoma

Phase I Trials

A Phase I Study of Ibrutinib in Patients with Recurrent or Persistent T-Cell Lymphoma
Kumar, Anita, MD
[Protocol 14-227]

A Phase IB Study of MPDL3280A plus Obinutuzumab in Patients with Recurrent or Persistent Lymphoma
Palomba, M. Lia, MD
[Protocol 14-220]

A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-265]

A Phase I/II Study of IMO-8400 in Patients with Persistent or Recurrent Waldenstrom's Macroglobulinemia
Palomba, M. Lia, MD
[Protocol 14-078]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

A Phase I Study of PU-H71 in Patients with Advanced Cancer
Gerecitano, John, MD, PhD
[Protocol 11-041]

A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Sauter, Craig, MD
[Protocol 14-145]

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 14-130]